Personalized medicine and inhibition of EGFR signaling in lung cancer.
Gazdar
Adi F
AF
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D005819:Genetic Markers; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D005819:Genetic Markers; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib
J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1
16505443
N Engl J Med. 2009 Sep 3;361(10):958-67
19692684
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60
18006754
Cell. 2000 Jan 7;100(1):57-70
10647931
J Clin Oncol. 2009 Jun 1;27(16):2589-91
19414671
J Clin Oncol. 2005 Aug 1;23(22):5007-18
16051952
PLoS One. 2009;4(2):e4576
19238210
N Engl J Med. 2009 Sep 3;361(10):947-57
19692680
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882